Herantis Pharma

1,4

EUR

+0,72 %

4.256 følger denne virksomhed

HRTIS

First North Finland

Biotechnology & Pharmaceuticals

Health Care

Overview

Finansielt overblik og estimater

Sammenligne

+0,72%

-0,71%

-7,59%

-9,97%

-4,11%

-28,54%

-79,56%

-86,1%

Herantis Pharma Plc is a clinical-stage biotechnology company developing disease modifying therapies for Parkinson’s disease. Herantis’ lead product HER-096 is a small synthetic chemical peptidomimetic molecule developed based on the active site of the CDNF protein. HER-096 combines the mechanism of action of CDNF with subcutaneous administration. The Phase 1a clinical trial demonstrated a good safety and tolerability profile as well as blood-brain barrier penetration of subcutaneously administered HER-096. The shares of Herantis are listed on the Nasdaq First North Growth Market Finland.

Læs mere

Markedsværdi

33,73 mio. EUR

Aktieomsætning

16,78 t EUR

P/E (adj.) (25e)

-7,38

EV/EBIT (adj.) (25e)

-8,31

P/B (25e)

253,51

EV/S (25e)

3.384,99

Udbytteafkast, % (25e)

Coverage

Anbefaling

Akkumulér

Kursmål

1.90 EUR

Opdateret

07.03.2025

Disclaimer

Antti Siltanen

Analytiker

Latest research

Seneste analyse

Released: 07.03.2025

Seneste omfattende analyse

Released: 25.06.2024

Omsætning og EBIT-margin

Omsætning t

EBIT-% (adj.)

EPS og udbytte

EPS (adj.)

Udbytte %

Finanskalender

24.4

2025

Generalforsamling '25

21.8

2025

Delårsrapport Q2'25

Risiko

Business risk

Valuation risk

Lav

Høj

Alle

Analyse

Selskabspræsentationer

Selskabsmeddelelser

Eksterne analyser

ViserAlle indholdstyper

Selskabsmeddelelse12.3.2025, 08.45

Herantis Pharma Oyj: Managers' Transactions – Tone Kvåle

Herantis Pharma

Herantis H2'24: Phase Ib completion is this year's theme

Analyse7.3.2025, 08.39 af

Antti Siltanen

Herantis H2'24: Phase Ib completion is this year's theme

Herantis Pharma's H2 was as expected, both in terms of numbers and trial progress.

Herantis Pharma

Videopræsentation6.3.2025, 12.30

Herantis Pharma, Webcast, Q4'24

Herantis Pharma

Join Inderes community

Don't miss out - create an account and get all the possible benefits

Inderes account

Followings and notifications on followed companies

Analyst comments and recommendations

Stock comparison tool & other popular tools

Create account

Herantis H2'24 flash comment: Trial progress and figures were as expected

Analytikerkommentar6.3.2025, 07.54 af

Antti Siltanen

Herantis H2'24 flash comment: Trial progress and figures were as expected

Herantis' H2'24 operating result was -2.27 MEUR, in line with our expectations. The company initiated a Phase Ib clinical trial in Parkinson's disease with HER-096 during the reporting period.

Herantis Pharma

Selskabsmeddelelse6.3.2025, 06.00

Herantis Pharma releases 2H and FY 2024 report today

Herantis Pharma

Herantis H2’24 preview: Phase I clinical trial to be completed this year

Analytikerkommentar4.3.2025, 07.24 af

Antti Siltanen

Herantis H2’24 preview: Phase I clinical trial to be completed this year

The company initiated a Phase Ib clinical trial in Parkinson's disease with HER-096 during the reporting period.

Herantis Pharma

Pressemeddelelse24.2.2025, 08.15

Herantis Pharma: Invitation to Full Year 2024 report webinar on March 6, 2025

Herantis Pharma

Selskabsmeddelelse18.2.2025, 14.00

Herantis Pharma: Disclosure of Major Holdings according to Chapter 9, Section 10 of the Finnish Securities Markets Act

Herantis Pharma

Selskabsmeddelelse17.2.2025, 07.20

Herantis Pharma Plc: 1,311,363 new shares registered with the trade register

Herantis Pharma

Selskabsmeddelelse10.2.2025, 06.35

Herantis Pharma Plc: 2,622,721 new shares registered with the trade register

Herantis Pharma

Analytikerkommentar7.2.2025, 06.39 af

Antti Luiro

Herantis Pharma collected 5.2 MEUR in gross assets from the directed share issue as expected

The funds raised in the issue will strengthen the company's financial position until the topline data of the HER-096 phase 1b trial are released in Q3'25. The company commented that it will continue its partnership discussions and preparations for the phase 2 trial.

Herantis Pharma

Selskabsmeddelelse6.2.2025, 18.30

Inside information: Herantis Pharma Plc successfully completes a directed share issue raising EUR 5.2 million

Herantis Pharma

Analytikerkommentar28.1.2025, 09.25 af

Antti Luiro

Herantis Pharma Phase 1b clinical trial is progressing

Herantis reported in a press release that the first patient with Parkinson's disease received a test dose of the drug in the second part of the Phase 1b clinical trial.

Herantis Pharma

Pressemeddelelse28.1.2025, 07.00

Antti Siltanen

Drug development investment: Value creation through M&As and licensing agreements

The fourth part of our series of articles focusing on investing in Life Science companies deals with value creation in drug development companies through M&As and licensing agreements.

Faron Pharmaceuticals Herantis Pharma Orion Modulight

Selskabsmeddelelse12.12.2024, 14.00

Herantis Pharma

1,4

EUR

+0,72 %

Coverage

Latest research

Omsætning og EBIT-margin

EPS og udbytte

Finanskalender

Risiko

Herantis Pharma Oyj: Managers' Transactions – Tone Kvåle

Herantis H2'24: Phase Ib completion is this year's theme

Herantis Pharma, Webcast, Q4'24

Join Inderes community

Inderes account

Herantis H2'24 flash comment: Trial progress and figures were as expected

Herantis Pharma releases 2H and FY 2024 report today

Herantis H2’24 preview: Phase I clinical trial to be completed this year

Herantis Pharma: Invitation to Full Year 2024 report webinar on March 6, 2025

Herantis Pharma: Disclosure of Major Holdings according to Chapter 9, Section 10 of the Finnish Securities Markets Act

Herantis Pharma Plc: 1,311,363 new shares registered with the trade register

Herantis Pharma Plc: 2,622,721 new shares registered with the trade register

Herantis Pharma collected 5.2 MEUR in gross assets from the directed share issue as expected

Inside information: Herantis Pharma Plc successfully completes a directed share issue raising EUR 5.2 million

Herantis Pharma Phase 1b clinical trial is progressing

Herantis Pharma: encouraging pharmacokinetic data and first subject with Parkinson’s disease dosed in the Phase 1b trial

Herantis Pharma Oyj: Managers' Transactions – Aki Prihti

Herantis Pharma Oyj: Managers' Transactions – Aki Prihti

Drug development investment: Value creation through M&As and licensing agreements

Herantis Pharma’s financial calendar and annual general meeting for 2025

Proposals of the Shareholders' Nomination Committee to Herantis Pharma Plc's Annual General Meeting 2025

Herantis Pharma as an Investment | Life Science Night Dec. 2, 2024